NASDAQ:PIRS Pieris Pharmaceuticals (PIRS) Stock Forecast, Price & News $0.90 +0.05 (+5.91%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$0.83▼$0.9050-Day Range$0.72▼$1.4852-Week Range$0.72▼$2.12Volume126,746 shsAverage Volume566,668 shsMarket Capitalization$73.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Pieris Pharmaceuticals MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.24% of Shares Sold ShortDividend StrengthN/ASustainability-0.57Upright™ Environmental ScoreNews Sentiment1.00Based on 3 Articles This WeekInsider TradingAcquiring Shares$8,500 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.71) to ($0.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector442nd out of 983 stocksPharmaceutical Preparations Industry213th out of 486 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Pieris Pharmaceuticals. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.24% of the outstanding shares of Pieris Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverPieris Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pieris Pharmaceuticals has recently decreased by 1.08%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPieris Pharmaceuticals does not currently pay a dividend.Dividend GrowthPieris Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePieris Pharmaceuticals has received a 76.91% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Pieris Pharmaceuticals is -0.57. Previous Next 2.8 News and Social Media Coverage News SentimentPieris Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Pieris Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for PIRS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Pieris Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pieris Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.30% of the stock of Pieris Pharmaceuticals is held by insiders.Percentage Held by Institutions47.31% of the stock of Pieris Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Pieris Pharmaceuticals are expected to grow in the coming year, from ($0.71) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pieris Pharmaceuticals is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pieris Pharmaceuticals is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPieris Pharmaceuticals has a P/B Ratio of 4.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Pieris Pharmaceuticals (NASDAQ:PIRS) StockPieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.Read More Receive PIRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PIRS Stock News HeadlinesJune 2, 2023 | finanznachrichten.dePieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare ConferenceJune 2, 2023 | finance.yahoo.comPieris Pharmaceuticals to Present at Jefferies 2023 Healthcare ConferenceJune 2, 2023 | UNKNOWN (Ad)This NASDAQ Stock Is The Amazon Of Medical SupplyThis Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More NowMay 22, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International ConferenceMay 21, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International ConferenceMay 17, 2023 | americanbankingnews.comPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) to Post Q2 2023 Earnings of ($0.16) Per Share, William Blair ForecastsMay 15, 2023 | finance.yahoo.comPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analysts Just Cut Their EPS Forecasts SubstantiallyMay 12, 2023 | seekingalpha.comPieris Pharmaceuticals GAAP EPS of -$0.18 misses by $0.04, revenue of $1.94M misses by $4.57MJune 2, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 11, 2023 | finance.yahoo.comPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call TranscriptMay 10, 2023 | msn.comRecap: Pieris Pharmaceuticals Q1 EarningsMay 10, 2023 | finanznachrichten.dePieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business UpdatesMay 10, 2023 | finance.yahoo.comPieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business UpdatesMay 9, 2023 | msn.comPreview: Pieris Pharmaceuticals's EarningsMay 8, 2023 | americanbankingnews.comPieris Pharmaceuticals (PIRS) to Release Quarterly Earnings on TuesdayMay 5, 2023 | finance.yahoo.comPieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shares Lagging The Industry But So Is The BusinessMay 4, 2023 | finanznachrichten.dePieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of ElarekibepMay 4, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)May 2, 2023 | finance.yahoo.comPieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023April 17, 2023 | finanznachrichten.dePieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa At 2023 AACR Annual MeetingApril 17, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual MeetingApril 5, 2023 | americanbankingnews.comWilliam Blair Comments on Pieris Pharmaceuticals, Inc.'s Q1 2023 Earnings (NASDAQ:PIRS)April 4, 2023 | americanbankingnews.comPieris Pharmaceuticals, Inc. Forecasted to Post Q1 2023 Earnings of ($0.19) Per Share (NASDAQ:PIRS)April 2, 2023 | americanbankingnews.comEquities Analysts Set Expectations for Pieris Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:PIRS)April 1, 2023 | finance.yahoo.comPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Earnings Call TranscriptMarch 31, 2023 | finance.yahoo.comPieris Pharmaceuticals Full Year 2022 Earnings: US$0.45 loss per share (vs US$0.71 loss in FY 2021)March 31, 2023 | americanbankingnews.comJefferies Financial Group Comments on Pieris Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:PIRS)See More Headlines PIRS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PIRS Company Calendar Last Earnings3/29/2023Today6/02/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PIRS CUSIPN/A CIK1583648 Webwww.pieris.com Phone(857) 246-8998Fax49-8161-141-1444Employees124Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,280,000.00 Net Margins-245.45% Pretax Margin-245.45% Return on Equity-133.94% Return on Assets-42.29% Debt Debt-to-Equity RatioN/A Current Ratio1.41 Quick Ratio1.41 Sales & Book Value Annual Sales$25.90 million Price / Sales2.69 Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book4.47Miscellaneous Outstanding Shares82,020,000Free Float76,032,000Market Cap$69.73 million OptionableOptionable Beta1.08 Key ExecutivesStephen S. YoderPresident, Chief Executive Officer & DirectorThomas BuresSenior VP, Chief Financial & Accounting OfficerKayti AvianoVice President-Clinical OperationsHitto KaufmannChief Scientific Officer & Senior Vice PresidentShane OlwillChief Development Officer & Senior Vice PresidentKey CompetitorsAlzamend NeuroNASDAQ:ALZNMainz BiomedNASDAQ:MYNZImmunomeNASDAQ:IMNMConnect BiopharmaNASDAQ:CNTBLongeveronNASDAQ:LGVNView All CompetitorsInsiders & InstitutionsChristopher P KiritsyBought 10,000 shares on 5/25/2023Total: $8,500.00 ($0.85/share)JPMorgan Chase & Co.Bought 203,463 shares on 5/18/2023Ownership: 0.305%State Street CorpBought 14,500 shares on 5/16/2023Ownership: 0.273%Affinity Asset Advisors LLCBought 306,950 shares on 5/15/2023Ownership: 0.374%BlackRock Inc.Sold 114,163 shares on 5/12/2023Ownership: 1.633%View All Insider TransactionsView All Institutional Transactions PIRS Stock - Frequently Asked Questions How have PIRS shares performed in 2023? Pieris Pharmaceuticals' stock was trading at $1.04 on January 1st, 2023. Since then, PIRS shares have decreased by 18.3% and is now trading at $0.8501. View the best growth stocks for 2023 here. When is Pieris Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our PIRS earnings forecast. How were Pieris Pharmaceuticals' earnings last quarter? Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) issued its quarterly earnings results on Wednesday, March, 29th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. The biotechnology company had revenue of $5.85 million for the quarter, compared to analysts' expectations of $6.51 million. Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 133.94% and a negative net margin of 245.45%. What other stocks do shareholders of Pieris Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Verastem (VSTM), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Dynavax Technologies (DVAX), Sangamo Therapeutics (SGMO), Allena Pharmaceuticals (ALNA) and Anavex Life Sciences (AVXL). What is Pieris Pharmaceuticals' stock symbol? Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS." Who are Pieris Pharmaceuticals' major shareholders? Pieris Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (1.63%), Platinum Investment Management Ltd. (1.31%), Acadian Asset Management LLC (0.85%), Renaissance Technologies LLC (0.52%), Candriam S.C.A. (0.47%) and Affinity Asset Advisors LLC (0.37%). Insiders that own company stock include Aquilo Capital Management, Llc, Christopher P Kiritsy, Shane Olwill and Tim Demuth. View institutional ownership trends. How do I buy shares of Pieris Pharmaceuticals? Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pieris Pharmaceuticals' stock price today? One share of PIRS stock can currently be purchased for approximately $0.85. How much money does Pieris Pharmaceuticals make? Pieris Pharmaceuticals (NASDAQ:PIRS) has a market capitalization of $69.73 million and generates $25.90 million in revenue each year. The biotechnology company earns $-33,280,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. How many employees does Pieris Pharmaceuticals have? The company employs 124 workers across the globe. How can I contact Pieris Pharmaceuticals? Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The official website for the company is www.pieris.com. The biotechnology company can be reached via phone at (857) 246-8998, via email at kelman@pieris.com, or via fax at 49-8161-141-1444. This page (NASDAQ:PIRS) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.